Bristol-Myers Squibb 10-Qquarter ended 2026-03-31

Executive Summary

Bristol Myers Squibb’s Q1 2026 revenue rose 3% Y/Y to $11.5B as newer products and Eliquis more than offset accelerating generic erosion in its legacy portfolio. GAAP earnings improved, but lower acquired-intangible amortization helped that result while non-GAAP earnings declined; operating cash flow also fell as rebate and discount payments rose sharply. The investment case rests on whether launches, pipeline approvals and planned savings can replace expiring product revenue before pricing pressure and patent losses deepen. A debt-heavy balance sheet and negative tangible common equity make that transition consequential for shareholders.

Key Financial Highlights

• Revenue mix: Growth Portfolio revenue rose 12% to $6.23B, while Legacy Portfolio revenue fell 6% to $5.28B. Gross product sales nevertheless dropped 15%; a lower gross-to-net adjustment rate, primarily related to the U.S. Eliquis list-price reduction, supported net product sales.
• Earnings quality: Acquired-intangible amortization fell to $437M from $830M, while R&D included $410M of acquired research-and-development impairment charges. Investment gains of $134M reversed a $78M loss a year earlier, adding another non-operating contrast.
• Cash and capital allocation: Rebate and discount payments used $3.50B of cash vs $627M Y/Y, partly offset by a $1.69B receivables inflow. Dividends paid of $1.28B exceeded free cash flow; common shares outstanding increased from 2.036B to 2.042B, and stock-based compensation was $146M.

Business Developments

Eliquis revenue grew 16% to $4.14B, making it both the largest reported growth driver and a concentrated source of exposure. Camzyos, Breyanzi and Reblozyl also expanded, while generic competition drove Revlimid down 63% to $349M and Sprycel down 58% to $73M. Opdivo declined 5%, primarily because of U.S. channel inventory and customer-order timing.

Pipeline and approval activity offers potential replacements: U.S. approvals included Sotyktu for active psoriatic arthritis and an Opdivo combination for previously untreated advanced classical Hodgkin lymphoma. Positive late-stage results included mezigdomide combinations and adolescent Camzyos; the U.S. iberdomide application has an 08/17/2026 decision date. These developments support the portfolio transition but do not yet offset the cash flow lost to established products.

Management targets $2.0B of annual productivity savings by the end of 2027. Its restructuring plan anticipates $2.5B of charges through 2027, of which $1.8B had been incurred, shifting resources across R&D, manufacturing and commercial operations as older products lose exclusivity.

Risk Assessment

• Patent and generic erosion: Revlimid generic licenses became unlimited by volume in January, U.S. Pomalyst generics entered in March, and European Eliquis patent protections expire in November 2026; further entry could outpace new-product growth.
• Pricing policy: Medicare-negotiated Eliquis prices began on 01/01/2026, with Pomalyst prices scheduled for 2027; the U.S. Government Agreement provides specified tariff and pricing relief while effective, but its termination or foreign pricing mandates could pressure revenue and cash flow.
• Cash generation and leverage: Q1 free cash flow of $757M did not cover $1.28B of dividends, while balance-sheet debt stood at $44.5B; sustained cash-flow weakness would narrow capital-allocation flexibility.
• Litigation: A contingent-value-rights claimant alleges BMS avoided a potential $6.4B Breyanzi-related milestone payment; patent, antitrust and drug-pricing proceedings could also materially affect results in an individual period.
• Development and asset values: The $410M acquired research-and-development impairment underscores the risk that clinical setbacks undermine expected returns on pipeline investment.
• Customer concentration: The three largest U.S. customers accounted for 70% of trade receivables, exposing collections to a small group of counterparties.

This 10-Q lists no risk factors of its own and refers to the annual report. The risks above come from the rest of this filing. Full list: FY2025 10-K.

Strategic Outlook and Investor Actionables

The near-term contest is between growth-product launches and savings on one side, and generic losses, negotiated prices and cash demands on the other. Monitor:

• Portfolio replacement: Growth Portfolio revenue growth vs declines in Revlimid, Pomalyst and other legacy products; sustained total revenue growth would support the transition.
• Cash conversion: Operating cash flow and free cash flow vs GAAP earnings and dividends; normalization of rebate payments would test whether Q1’s shortfall was temporary.
• Pipeline and productivity: The 08/17/2026 iberdomide decision and progress toward $2.0B in annual savings by the end of 2027; delays or additional impairments would weaken the replacement thesis.